Portal hypertensive gastropathy (PHG) as defined by congestive changes in the gastric mucosa owing to increased portal pressure, was first described about ten years ago. Whereas definition and grading of severity are still under debate, there is general agreement that PHG is a new clinical entity. PHG is present in 50-80% of patients with liver cirrhosis. PHG is a major cause of upper gastrointestinal bleeding in patients with portal hypertension (25-90% depending on severity). Presence of portal hypertension is a prerequisite for the development of PHG, and reduction of portal pressure and splanchnic blood flow with beta-adrenergic blockers has shown promising results, but an established medical treatment of PHG does not exist. Trials with new vasoactive drugs are awaited.
Udgivelsesdato: 1995-Nov-13